mRNA Vaccines

Dear Colleagues,

This Special Issue is a continuation of our previous Special Issue “SARS-CoV-2 and mRNA Vaccines” (https://www.mdpi.com/journal/viruses/special_issues/SARS-CoV-2-mRNA-Vaccine).

In order to effectively prevent and control COVID-19, which has caused great harm and had a significant impact on the world in recent years, great attention has been paid to the development and application of COVID-19 vaccines with various technological routes. Among them, mRNA vaccines have been greatly and rapidly developed and applied around the world. The advantages of good immunogenicity and rapid editable development and production have been demonstrated around the world. This is a promising development in both vaccines and therapeutic biologics. Recently, after linear mRNA, circular mRNA has once again been attracting attention worldwide, because it has the advantages of linear mRNA, but also solves the key problem of linear mRNA products—stability.

In order to summarize and promote the development of mRNA technology, a Special Issue on the topic of SARS-CoV-2/mRNA vaccines will be issued in our journal, including descriptions of R&D, manufacturing processes, quality control, clinical trials, practical applications, mechanisms, and other research on COVID-19 mRNA and circular mRNA vaccines. We hope that the reports collected in this issue will provide a good reference for the development and quality control of mRNA products worldwide.

Prof. Dr. Zhenglun Liang
Prof. Dr. Qunying Mao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• SARS-CoV-2
• mRNA Vaccines design
• manufacturing process
• quality control
• clinical trials
• practical application
• mechanism
• effectiveness
• safety